Spastic Paraplegia, Hereditary
Conditions
Keywords
spastic paraplegia, metabolism, oxysterols, neurogenetics
Brief summary
The purpose of this project is to study the efficacy of three candidate molecules (Xenbilox, Tahor and Resveratrol) in order to decrease the production of oxysterols by reducing the synthesis of cholesterol and/or regulate the production of bile acids and/or enabling neuroprotective action within the motor neuron.
Detailed description
The primary objective of the study is: \- decrease the accumulation of metabolites which can have a negative impact on neurological and systemic function of patients with SPG5. The secondary objectives of the study are: * confirm the clinical and biological tolerance of the different candidate molecules under study * improve the serum bile acid profile of patients with SPG5
Interventions
DRUGXenbilox
DIETARY_SUPPLEMENTResveratrol
DRUGTahor
Sponsors
Institut National de la Santé Et de la Recherche Médicale, France
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients that have confirmed through genetic testing their status as carriers of 2 mutations in the CYP7B1 gene * age ≥ 18 years * patients that have signed the informed consent form * presence of health care coverage
Exclusion criteria
* known hypersensitvity to chenodeoxycholic acid, atorvastatin, resveratrol or to any of their byproducts * cholesterol lowering medications other than the study treatment * hepatic failure with transaminases \>3 times the normal level * progressive biliary pathology * chronic diarrhea * serious mental illness * significant comorbid neurological disorder * incapacity to understand information about the protocol * unwilling or unable to participate in any part of the study * participation in another clinical trial during the study period * person deprived of liberty by judicial or administrative decision * adult subject under legal protection or unable to consent * pregnant or breastfeeding women * lack of health care coverage * absence of a signed informed consent form
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of 27-hydroxycholesterol blood level after 2 months of treatment for each treatment | 2 months | 27-hydroxycholesterol will be measured on fasten blood samples for the 12 patients included before and after the 2-month treatment period for each treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Modification of the serum acid profile after a 2-month treatment measured in blood and urine samples | 2 months | In blood and urines samples of the 12 patients, the following criteria will be assesed in order to observe an evolution of the acid profile: * total biliary acids * ratio of primary/secondary biliary acids * the ratio cholic acids/chenodeoxycholic acids * the ratio chenodeoxycholic acids/ lithocholic acids |
| Change of 25-hydroxycholesterol blood level after 2 months of treatment for each treatment | 2 months | 25-hydroxycholesterol will be measured on fasten blood samples for the 12 patients included before and after the 2-month treatment period for each treatment |
| Number of participants with adverse events related with digestive problems | 18 months | During the study, adverse events related with digestive problems will be evaluate in order to asses the clinical tolerance to each treatment |
| Number of partcipants with adverse events related with standard biological parameters | 18 months | Biological tolerance will be evaluate on patients blood samples at each visit. The following criteria will be assessed: * ionogram and fasting glucose * kidney and liver function with urea, creatinine,lipase, amylase, bilirubine, creatine phosphokinase, transaminases,sodium, potassium, calcium, phosphorus |
Countries
France
Outcome results
None listed